Form 4: Dexcom Director Transfers Shares to Family Trust
SEC Form 4 Filing
Mark G. Foletta, a director at Dexcom Inc., transferred 3,306 shares of common stock from direct ownership to a family trust on May 18, 2024.
Summary
- On May 18, 2024, Mark G. Foletta, a director of Dexcom Inc., transferred 3,306 shares of Dexcom common stock from his direct ownership to the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15.
- The transfer occurred upon the vesting of previously awarded restricted stock units.
- Following the transaction, Foletta directly owns 0 shares and indirectly owns 62,398 shares through the family trust.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a share transfer, with no inherent positive or negative sentiment.
Industry Context
This is a routine disclosure related to insider transactions and is common for directors and officers of publicly traded companies.
Stakeholder Impact
- The transaction has minimal direct impact on stakeholders as it is a transfer of ownership between the director and a related family trust.
Key Dates
| Date | Description |
|---|---|
| 01/30/2015 | Date of the Foletta Family Trust (DTD 1/30/15) |
| 05/18/2024 | Date of the share transfer transaction |
| 05/21/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.